[Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
OBJECTIVE
To further evaluate the efficacy and side-effects of domastic amsacrine.


METHODS
Two handred and ninty-one patients with acute leukemias, including initial, relapsed and refractory cases, were treated with regimens combining the amsacrine with other antileukemic drugs.


CONCLUSIONS
The total CR rate was 43.3% in ALL and 49.0% in ANLL. The CR rates of relapsed/refractory ALL and ANLL was 28.9% and 34.4%, respectively. The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens. The pharmacokinetic parameters of the domastic amsacrine, C12h/C6h, K21 were correlated with therapeutic effectiveness.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D000677:Amsacrine